Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Mayumi Kobayashi-KatoMayu YunokawaSeiko BunNaoyuki MiyasakaTomoyasu KatoKenji TamuraPublished in: Cancer chemotherapy and pharmacology (2019)
PS 1-2 and PFI < 3 months were significant predictors of poor response to following treatment for PRROC. Risks and benefits of treatment should be frankly discussed with patients who have these characteristics.